Browse by Section 100 Item List

HIGHLY SPECIALISED DRUGS PROGRAM (Public Hospital)

For Highly Specialised Drugs prescribed through public hospitals, claiming and approval of authority prescriptions is administered by Services Australia. Maximum quantities and repeats for Highly Specialised Drugs are listed in the Schedule. Highly Specialised Drugs prescribed through public hospitals, except Complex Authority Required Highly Specialised Drugs, are Authority required (STREAMLINED) PBS Prescriptions. Authority approvals are required for prescriptions where the dose is above the determined maximum quantity and/or number of repeats. Complex Authority Required Highly Specialised Drugs require written authority applications. Approval of authority prescriptions by Services Australia may be obtained either by posting an Authority Prescription Form to Services Australia, or by using the Services Australia Authority free-call service (1800 888 333). Prescribers must quote the provider number of the hospital when applying.

Public hospital prescriptions for Highly Specialised Drugs can be dispensed by public hospital pharmacies. A patient will be required to pay a contribution for each supply of a highly specialised drug at a similar rate to the Pharmaceutical Benefits Scheme. Commonwealth subsidy is not available for hospital in-patients.

Reciprocal Health Care Agreement – Where a patient is entitled to be treated as an eligible person as a visitor from a country with which Australia has entered into a Reciprocal Health Care Agreement, the supply will be limited to the original prescription only. Repeat prescriptions for these patients are not permitted.

  • Legend
  • MPMedical Practitioner
Prescriber code Item code Name, manner of administration and form & strength Max qty
packs
Max qty
units
No. of
repeats
MP 11242Q OCRELIZUMABocrelizumab 300 mg/10 mL injection, 10 mL vial 2 2 0
MP 9508K OCTREOTIDEoctreotide 50 microgram/mL injection, 5 x 1 mL ampoules 18 90 11
MP 9510M OCTREOTIDEoctreotide 500 microgram/mL injection, 5 x 1 mL ampoules 18 90 11
MP 10533J OCTREOTIDEoctreotide 20 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack 2 2 5
MP 10543X OCTREOTIDEoctreotide 10 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack 2 2 5
MP 10550G OCTREOTIDEoctreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack 2 2 5
MP 11893Y OCTREOTIDEoctreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack 2 2 5
MP 9509L OCTREOTIDEoctreotide 100 microgram/mL injection, 5 x 1 mL ampoules 18 90 11
MP 10109C OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 1 1 7
MP 10973M OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 1 1 6
MP 11168T OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 2 2 5
MP 11176F OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 2 2 2
MP 11824H OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 1 1 5
MP 11828M OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 1 1 0
MP 11945Q OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 1 1 5
MP 11950Y OMALIZUMABomalizumab 150 mg/mL injection, 1 mL syringe 1 1 0
MP 10118M OMALIZUMABomalizumab 75 mg/0.5 mL injection, 0.5 mL syringe 1 1 7
MP 10967F OMALIZUMABomalizumab 75 mg/0.5 mL injection, 0.5 mL syringe 1 1 6
MP 11835X OMALIZUMABomalizumab 75 mg/0.5 mL injection, 0.5 mL syringe 1 1 5
MP 11846L OMALIZUMABomalizumab 75 mg/0.5 mL injection, 0.5 mL syringe 1 1 0
MP 11946R OMALIZUMABomalizumab 75 mg/0.5 mL injection, 0.5 mL syringe 1 1 5
MP 11962N OMALIZUMABomalizumab 75 mg/0.5 mL injection, 0.5 mL syringe 1 1 0